Apellis (APLS) is up 136.0%, or $23.25 to $40.34.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Morning Movers: Marvell jumps following Nvidia investment, AI factory pact
- Video: Deals in food and pharmaceuticals headline busy morning of M&A
- M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
- Biogen to acquire Apellis for $41.00 per share in cash at closing, or $5.6B
- Apellis price target lowered to $31 from $35 at Cantor Fitzgerald